A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Inclusion Criteria:

- Aged 50 - 79 years inclusive.

- Meeting the diagnosis of probable Alzheimer's Disease

- Of moderate severity (Mini-Mental Status Exam [MMSE] score 10 - 20 inclusive).

- Patients must be in generally good health as indicated by their medical history and
physical examination, vital signs, electrocardiogram (ECG), and standard laboratory
tests.

Exclusion Criteria:

- Women of child bearing potential.

- History or presence of a seizure disorder.

- History of peptic ulcer disease, urinary or gastric retention; asthma or obstructive
pulmonary disease.

- History or presence of bladder outflow obstruction, gastrointestinal obstructive
disorder or reduced GI motility, or narrow-angle glaucoma.

- History or presence of gastrointestinal, hepatic, or renal disease, or other
condition known to interfere with the absorption, distribution, metabolism or
excretion of drugs.

- History or presence of myasthenia.

- Known hypersensitivity to donepezil, solifenacin or related drugs.

- Any other clinically relevant acute or chronic diseases which could interfere with
patients' safety during the trial, or expose them to undue risk, or which could
interfere with study objectives.

- Patients who have participated in another clinical trial with an investigational drug
within previous 30 days.